CN107530346A - 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 - Google Patents

布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 Download PDF

Info

Publication number
CN107530346A
CN107530346A CN201680026436.5A CN201680026436A CN107530346A CN 107530346 A CN107530346 A CN 107530346A CN 201680026436 A CN201680026436 A CN 201680026436A CN 107530346 A CN107530346 A CN 107530346A
Authority
CN
China
Prior art keywords
crystal type
solvate
xrpd
same
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680026436.5A
Other languages
English (en)
Chinese (zh)
Inventor
艾瑞克·戈德曼
M·S·史密斯
蒂埃里·伯诺德
阿尔贝托·穆诺兹加西亚
克里斯多佛·彼得·沃洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacyclics LLC
Original Assignee
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics LLC filed Critical Pharmacyclics LLC
Publication of CN107530346A publication Critical patent/CN107530346A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680026436.5A 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式 Pending CN107530346A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139594P 2015-03-27 2015-03-27
US62/139,594 2015-03-27
PCT/US2016/024305 WO2016160598A1 (en) 2015-03-27 2016-03-25 Solvated forms of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
CN107530346A true CN107530346A (zh) 2018-01-02

Family

ID=57006292

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026436.5A Pending CN107530346A (zh) 2015-03-27 2016-03-25 布鲁顿氏酪氨酸激酶抑制剂的溶剂化形式

Country Status (11)

Country Link
US (4) US20180072738A1 (enExample)
EP (1) EP3273961A4 (enExample)
JP (2) JP2018509457A (enExample)
CN (1) CN107530346A (enExample)
AU (1) AU2016243116A1 (enExample)
BR (1) BR112017020744A2 (enExample)
CA (1) CA2981048A1 (enExample)
HK (2) HK1249737A1 (enExample)
MA (1) MA41827A (enExample)
MX (1) MX2017012430A (enExample)
WO (1) WO2016160598A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114829370A (zh) * 2019-09-18 2022-07-29 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US11001585B2 (en) 2015-08-19 2021-05-11 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
CZ2016276A3 (cs) * 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
CN114478547A (zh) * 2020-10-23 2022-05-13 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130338172A1 (en) * 2012-06-04 2013-12-19 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103923084A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
DE3303707A1 (de) * 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
CO5210907A1 (es) * 1999-05-12 2002-10-30 Novartis Ag Solvatos de pometrozina, insecticidamente activos, composiciones que contienen estos compuestos y metodos tanto para producir dichos compuestos y composiciones como para controlar plagas animales con estas composiciones
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US8541391B2 (en) * 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) * 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130338172A1 (en) * 2012-06-04 2013-12-19 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
CN103923084A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114829370A (zh) * 2019-09-18 2022-07-29 普莱鲁德疗法有限公司 蛋白质精氨酸甲基转移酶5(prmt5)的选择性抑制剂

Also Published As

Publication number Publication date
US20190367519A1 (en) 2019-12-05
AU2016243116A1 (en) 2017-10-19
JP2022033783A (ja) 2022-03-02
EP3273961A4 (en) 2018-10-31
HK1248147A1 (zh) 2018-10-12
HK1249737A1 (zh) 2018-11-09
WO2016160598A1 (en) 2016-10-06
US20180072738A1 (en) 2018-03-15
CA2981048A1 (en) 2016-10-06
US20200347063A1 (en) 2020-11-05
BR112017020744A2 (pt) 2018-07-17
JP2018509457A (ja) 2018-04-05
MX2017012430A (es) 2018-07-06
MA41827A (fr) 2018-01-30
US20220106317A1 (en) 2022-04-07
EP3273961A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US20240409545A1 (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
US20220242868A1 (en) Co-crystals of a bruton's tyrosine kinase inhibitor
CA2976695C (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
US20220106317A1 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
HK1249015B (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1248147

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180102

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1248147

Country of ref document: HK